Akebia Therapeutics (AKBA) Profit After Tax Growth (3y) (2016 - 2026)
Akebia Therapeutics (AKBA) Profit After Tax Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 51.23% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 2.94% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -70.53% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 4.50% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -7.75% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 66.11% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -17.90% |
| 10 | Akebia Therapeutics | 339.15 Mn | 176.55 Mn | 41.25 Mn | 30.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.42% |
| Dec 31, 2025 | -26.34% |
| Sep 30, 2025 | 26.20% |
| Jun 30, 2025 | -79.68% |
| Mar 31, 2025 | 27.98% |
| Dec 31, 2024 | 31.15% |
| Sep 30, 2024 | 30.44% |
| Jun 30, 2024 | 53.07% |
| Mar 31, 2024 | 36.30% |
| Dec 31, 2023 | 26.14% |
| Sep 30, 2023 | 37.71% |
| Jun 30, 2023 | 60.09% |
| Mar 31, 2023 | 23.80% |
| Dec 31, 2022 | 59.95% |
| Sep 30, 2022 | 0.30% |
| Jun 30, 2022 | 35.83% |
| Mar 31, 2022 | 4.28% |
| Dec 31, 2021 | -5.17% |
| Sep 30, 2021 | -31.73% |
| Jun 30, 2021 | -34.58% |